Scleroderma, Localized
9
4
4
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.1%
1 terminated out of 9 trials
80.0%
-6.5% vs benchmark
11%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
Patients Diagnosed With Scleroderma: Physical Performance and Functionality
Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea
Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix
Imiquimod in Children With Plaque Morphea
Efficacy and Safety of Imatinib in Scleroderma